Among the overall cohort, the following all‐grade treatment‐related adverse events (TRAEs) were observed in 5% or more of the patients: decreased appetite, decreased white blood cell count and neutrophil count, asthenia, nausea, increased aspartate aminotransferase (AST) and alanine aminotransferase (ALT), vomiting, alopecia, anemia, increased blood bilirubin, rash, diarrhea, increased blood creatinine, and pruritus. Here, GPT is linked to asthenia.